<DOC>
	<DOCNO>NCT02326155</DOCNO>
	<brief_summary>An observational , prospective cohort study evaluate safety efficacy Remsima™ patient Crohn 's disease ( CD ) Ulcerative Colitis ( UC )</brief_summary>
	<brief_title>To Evaluate Safety Efficacy Remsima™ Patients With Crohn 's Disease ( CD ) Ulcerative Colitis ( UC )</brief_title>
	<detailed_description>The primary objective study assess safety Remsima™ evaluation Events Special Interest ( ESI ) IBD patient , active Crohn 's disease ( CD ) , fistulizing Crohn 's disease ( CD ) , Ulcerative Colitis ( UC ) 5 year patient . The secondary objective study evaluate additional safety efficacy Remsima™ IBD patient , active CD , fistulizing CD UC . Health-economic parameter also assess</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Adult patient moderate severe active CD 2 . Children adolescent patient , age 6 17 year old severe active CD 3 . Adult patient fistulizing active CD 4 . Adult patient moderate severe active UC 5 . Patients ( legal guardian , applicable ) willing give inform consent long term followup include access medical record . 1 . Patients history hypersensitivity infliximab 2 . Patients current past history chronic infection 3 . Patients moderate severe heart failure ( NYHA class III/IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>